OnCognia
A precision discovery platform combining community intelligence & expert-calibrated AI model simulation to unlock high-impact ADC and combination therapies overlooked by traditional pipelines
Problems We Are Trying to Solve
Traditional drug discovery pipelines are not suited for the combinatorial complexity of antibody-drug conjugates (ADCs):
Discovery blind spot: exploring only a small fragment of combo design space (genes, linkers, antibodies, payloads), confined to linear stage-gated development process, preference for proprietary assets.
Functional silos, missed insights: no one optimizes the ADC from end-to-end, biologists chase novel targets, chemists pick linkers for manufacturability and stability, protein engineers focus on antibody optimization for expression and binding affinity, pharmacologists police safety. 93% failure by phase 2 trial.
One-dimensional AI: narrowly focused AI optimized for single-agent prediction, not built for cross-domain, combinatorial therapy design; blackboxed AI also lacks mechanistic clarity
Result: billion-dollar promising chemo + mAb synergies remain unexplored
Why OnCognia?
What’s needed isn’t more data or another black-box AI model, but a bold new system for translational discovery. OnCognia is our answer:
Connects siloed expertise across discovery, development, and clinical domains to accelerate learning and de-risk decisions
Turns tacit expert knowledge into structured, computable input, making it actionable at scale
Systematically surfaces high-potential, overlooked therapy combinations missed by traditional pipelines
With OnCognia, biopharma companies gain decision-grade insights to prioritize/allocate development effort (e.g., high-probability combo, “Red-flag” development, evidence packages and cohort definitions).
Contact Us
Email: [email protected]